Sanofi has been leading pharmaceutical innovation for over 100 years. Globally, the company has more than 100,000 employees in over 100 countries and is headquartered in Paris, France. Sanofi is organized into five global units, and their work in Norway is focused on four different therapeutic areas: primary care, consumer healthcare, specialty care, and vaccines. Sanofi-Aventis’ Norway branch is in Lysaker and employs 82 people.
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. For more than 130 years, the family-owned company has developed new medicines for people and animals. Boehringer Ingelheim’s nearly 50,000 employees work to implement the company’s mission to spread value through innovation in three core areas: human medicine, veterinary medicine, and biopharmaceutical contract-based production. The company demonstrates its social responsibility by actively participating in the “Making More Health” initiative and prioritizing environmental protection and sustainability in all levels of operation. In Norway, Boehringer Ingelheim employs 71 people. In 2018, Boehringer Ingelheim’s Norwegian Branch achieved a total net sales revenue of NOK 423,000,000.
OSM Aviation is a global aviation management company offering tailored services within all aspects of recruitment, training, HR management, and planning to a wide range of international airlines. OSM Aviation entered the market in 2013 and has grown rapidly to approximately 6000 employees and operations in nineteen countries world-wide in a span of five years.
Aircontact Group is a privately-owned holding company within travel, aviation, support services, and offshore & biotechnology. The company’s flagship, Berg-Hansen Reisebureau, is the largest business travel agency in Norway and is internationally affiliated with the prestigious Carlson Wagonlit Travel. The air brokering unit, Aircontact, is the largest air broker in Scandinavia and the oldest in Europe, delivering tailormade charter solutions for governments and businesses. Aircontact Group is also a Nordic regional sales and marketing consultant for Sikorsky Aircraft, Lockheed Martin, Derco Aerospace, and Collins Aerospace, employing 478 people across the Nordics with an annual gross turnover of NOK 5.2 billion.
Discovery Networks Norway is a Norwegian media group owned by the American television network Discovery Communications. In Norway, Discovery owns and operates TVNorge, while also assisting its partner organizations in England and France in regard to their broadcasting for the Norwegian market. The Discovery portfolio includes FEM, MAX, VOX, TLC, Discovery Channel, Eurosport, Eurosport 2, and Eurosport Norge. The Discovery group also operates the streaming service Dplay.
Norsk Titanium AS is the world’s pioneering supplier of aerospace-grade, additive manufactured, structural titanium components. The company is distinguished in the aviation industry by its patented Rapid Plasma Deposition™ (RPD™) process that transforms titanium wire into complex components suitable for structural and safety-critical applications. Norsk Titanium is committed to cost-reducing aero structures and jet engines for the world’s premier aerospace manufacturers. RPD™ is the world’s first FAA-approved, 3D-printed, structural titanium, delivering substantial lead-time and cost savings for aerospace, defense, and commercial customers. NTi’s headquarters and technology center are located in Eggemoen and Ringerike, respectively, with the production center located in Plattsburgh, NY.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.